Vivos Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on January 16, 2026, covering events occurring on January 15, 2026. Vivos Therapeutics, Inc. (VVOS), an emerging growth company based in Littleton, Colorado, entered into a material definitive agreement to secure bridge financing.
Key Financial Metrics and Transaction Details
- Debt Instrument: Unsecured convertible promissory note with a maximum principal amount of up to $5,500,000.
- Initial Funding: $900,000 funded on January 15, 2026.
- Financing Fee: The maximum principal includes a 10% original issuance discount as a fee to the lender.
- Interest Rate: 0% under normal conditions; 15% per annum accrues only upon an Event of Default.
- Lender: V-Co Investors 3 LLC, an affiliate of New Seneca Partners Inc., an existing private equity investor and advisor.
Material Changes and Terms
The Company has established a bridge loan facility to support a proposed equity financing ("Subsequent Financing") of up to $5,500,000. The note is designed to convert automatically into equity instruments issued in the Subsequent Financing on a dollar-to-dollar basis if the financing closes by the "Outside Date" of February 16, 2026. If the financing does not close by this date, the Company may repay the principal and accrued interest without penalty.
Outlook, Risks, and Contingencies
The primary contingency is the successful closing of the Subsequent Financing by February 16, 2026. The filing notes that the Subsequent Financing may, but is not required to be, led by V-Co. Risks include the potential for an Event of Default, which would trigger a 15% annual interest rate. The transaction was executed as a private placement exempt from registration under Section 4(a)(2) of the Securities Act.
Investor Verification Checklist
- Confirm the status of the proposed $5,500,000 equity financing by the February 16, 2026 deadline.
- Review the full text of the Convertible Promissory Note (Exhibit 4.1) for specific covenants and default triggers.
- Monitor subsequent filings for the conversion of the note into equity or repayment terms if the financing is delayed.
- Verify the relationship and potential conflicts of interest with V-Co Investors 3 LLC and New Seneca Partners Inc.